에서 실시간으로 운영 중이에요! 자세히 알아보기
ANEB 아이콘

Anebulo Pharmaceuticals

상장 폐지됨

ANEB 종목은 2026년 2월 27일에 상장 폐지됐어요.

 

소개: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.

직원 수: 3

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 0%
중립 0%
부정적 0%
중립
Business Wire
9개월 전
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subsequent Highlights: On February 6, 2026, Anebulo announced that the Company's board of directors (the “Board”) approved th.
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
중립
Business Wire
9개월 전
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Company's board of directors (the “Board”) has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securi.
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
중립
Business Wire
9개월 전
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the fi.
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
중립
Business Wire
9개월 전
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer.
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
중립
Business Wire
11개월 전
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Volunta.
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
중립
Business Wire
작년
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates.
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
중립
Business Wire
작년
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
중립
Business Wire
작년
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or “Anebulo”), today announces the first subjects dosed in its Phase 1 single ascending dose (“SAD”) study of intravenous (IV) selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). First Subjec.
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
중립
Business Wire
작년
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives.
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
중립
Business Wire
작년
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the “Board”) has approved, as part of a going private transaction, a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than.
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
Lightweight Charts™를 사용해 가격 차트를 구현했어요.